Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease.
Paolo GisondiDavide GeatMartina MaurelliLuca Degli EspostiFrancesco BellinatoGiampiero GirolomoniPublished in: Vaccines (2022)
The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab.